Clinical Utility (CU) Evaluation of the Health-Related Quality-of-Life (HRQoL) QLQ-GINET21 Questionnaire (QNR) in the Treatment of Patients (pts) with Gastrointestinal (GI) Neuroendocrine Tumors (NETs). QUALINETS Study Abstract #2146

Introduction: QLQ-GINET21 for pts with GI-NETs covers muscle/bone pain, body image, information, sexual function, symptoms, social function and disease-related concerns.
Aim(s): To assess QLQ-GINET21 CU for clinical and therapeutic decisions in practice.
Materials and methods: In non-interventional QUALINETS (NCT02853422), 36 specialists completed an ad hoc survey to assess QLQ-GINET21 CU in pts with GI-NETs who completed QLQ-C30 and QLQ-GINET21. Items were rated 0 to 4; CU was scored low/moderate/high (primary endpoint: % pts) in 3 dimensions: a) therapeutic and clinical decisions (7 items: 0¬–9/10–19/20–28); b) doctor–patient communication (3 items: 0–4/5–8/9–12); and c) QNR characteristics (4 items: 0–5/6–11/12–16). HRQoL and relationships between CU, QNR scores, health status (HS) and clinical variables were investigated (ANOVA for categorical variables).
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Guillermo de La Cruz

To read results and conclusion, please login ...

Further abstracts you may be interested in

#36 A monocentric analysis of patients with pulmonary neuroendocrine tumors over 15 years: long term survival and life quality dependent from histological subtypes and surgical management
Introduction: Pulmonary neuroendocrine tumors substantially differ from epithelial tumors in terms of tumor biology and prognosis. In specialized interdisciplinary centers, a broad therapeutical armentarium can be used to achieve optimal treatment.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof. Johannes N Hoffmann
Authors: Zahn S, Hornung H, Schick K S, Winter H, ...
#43 Relationship between neuroendocrine tumor-related symptoms and RAND-36 health-related quality of life scores
Introduction: Neuroendocrine tumors (NETs) can secrete hormones that cause flushing and diarrhea (carcinoid syndrome) and disrupt health-related quality of life (HRQL).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Jennifer L Beaumont
Authors: Beaumont J L, Liu Z, Choi S, Yao J C, ...
#44 Somatostatin analogue therapy and RAND-36 health-related quality of life scores in patients with neuroendocrine tumors
Introduction: Somatostatin analogues (SSAs) are used in patients with neuroendocrine tumors (NETs) for the management of carcinoid syndrome and/or delay of disease progression.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Jennifer L Beaumont
Authors: Yao J C, Beaumont J L, Choi S, Cella D, ...
#45 Neuroendocrine tumor disease state and RAND-36 health-related quality of life scores
Introduction: Health-related quality of life (HRQL) can be disrupted in patients with malignancies.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Jennifer L Beaumont
Authors: Phan A, Beaumont J L, Liu Z, Choi S, ...
#138 The use of F-18-FDG-PET for patients with neuroendocrine tumors
Introduction: Neoplastic tissue exhibits high glucose utilization, which can be imaged by 18F-Fluorodeoxyglucose-positron emission tomography (FDG-PET). Whether FDG-PET is useful for neuroendocrine (NE) tumors, however, is questionable, due to the slow growth rate often observed in these tumors.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: M.Sc. Tina Binderup